This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
Study Type
OBSERVATIONAL
Enrollment
120
Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day)
TKI-Based Therapy
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
RECRUITINGLiaoning Cancer Hospital
Shenyang, Liaoning, China
RECRUITINGAppetite improvement level
Proportion of subjects with an improvement in appetite based on A/CS-12 after 12 weeks of treatment
Time frame: From baseline to Week 12 (end of treatment period)
Weight improvement level
Proportion of subjects who did not lose weight relative to baseline after 12 weeks of treatment
Time frame: From baseline to Week 12 (end of treatment period)
progression-free survival (PFS)
defined as the duration from the start treatment to progression, or patient death
Time frame: From the date of randomization until the first documented disease progression or death from any cause, whichever occurs first，assessed up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.